Browse News
Filter News
Found 809,090 articles
-
Despite being hit with a continuing decline in COVID-19 sales and a strong Swiss franc, Roche on Wednesday reported first-quarter sales were up 2% at constant exchange rates.
-
The FDA on Tuesday approved Day One Biopharmaceuticals’ type II RAF inhibitor Ojemda, which is designed to penetrate the blood-brain barrier, for the treatment of relapsed or refractory pediatric low-grade glioma.
-
An undisclosed once-daily oral dose of Neurocrine Biosciences’ Takeda-partnered investigational drug significantly reduced symptom severity in adults with major depressive disorder.
-
Policy changes by health insurance companies will likely determine which Humira biosimilars rise to the top.
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
4/24/2024
REGENXBIO Inc. announced it will participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 29, 2024.
-
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
4/24/2024
Alkermes plc announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in patients with narcolepsy type 1.
-
Meihua International Medical Technologies Co., Ltd. Reports 2023 Financial Year Results
4/24/2024
Meihua International Medical Technologies Co., Ltd., a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries in China, reported its financial results for the fiscal year ended December 31, 2023.
-
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
4/24/2024
RedHill Biopharma Ltd. announced that the first patient has been enrolled in the Austere environments Consortium for Enhanced Sepsis Outcomes' U.S. government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment.
-
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
4/24/2024
Travere Therapeutics, Inc., and CSL Vifor announced that the European Commission has granted conditional marketing authorization for FILSPARI for the treatment of adults with primary IgA nephropathy with a urine protein excretion ≥1.0 g/day.
-
ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
4/24/2024
ASLAN Pharmaceuticals announced that an abstract on eblasakimab in Chronic Obstructive Pulmonary Disease has been accepted for a late breaking poster presentation at the American Thoracic Society International Conference 2024.
-
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
4/24/2024
atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that the first patient has been dosed in Part 2 of Beckley Psytech’s Phase 2a study, evaluating BPL-003 in patients living with Treatment Resistant Depression.
-
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
4/24/2024
Chemomab Therapeutics Ltd. announced the company will report its first quarter 2024 financial results and provide a business update on May 9, 2024, at 7:00 am Eastern Time.
-
LSL Pharma Group Secures $3.8 Million as the Second and Final Tranche of Its Private Placement of Units
4/24/2024
LSL PHARMA GROUP INC., a Canadian integrated pharmaceutical company, announced the second and final tranche of its private placement financing of Units for $3.8 million representing the second closing of the upsized $7.5 million non-brokered private placement announced on April 11, 2024.
-
Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
4/24/2024
Chimerix announced that it will host a live conference call and audio webcast on Wednesday, May 1, 2024 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2024, and to provide a business overview.
-
PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024
4/24/2024
PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, announced that it will report its first quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 8, 2024.
-
Thermo Fisher Scientific Reports First Quarter 2024 Results
4/24/2024
Thermo Fisher Scientific Inc., the world leader in serving science, reported its financial results for the first quarter ended March 30, 2024.
-
Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair
4/24/2024
Harness Therapeutics, a biotechnology company focused on protein upregulation to develop next generation therapeutics for neurodegenerative diseases, announced the appointment of Ms. Meenu Chhabra Karson as Chair of its Board of Directors.
-
BioInvent International AB: Interim Report January-March 2024
4/24/2024
During the first quarter of the year, we continued making excellent progress with our clinical pipeline targeting TNFR2 and FcyRIIB, building on the momentum we generated during a very successful 2023.
-
Xaira Therapeutics Launches to Deliver Transformative Medicines by Advancing and Harnessing AI for Drug Discovery and Development
4/24/2024
Xaira Therapeutics launched on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies.